Lakewood-Amedex Inc.

21 articles with Lakewood-Amedex Inc.

• Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)

  4/5/2022

  Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).

• LAKEWOOD-AMEDEX APPOINTS TWO NEW BOARD MEMBERS

  1/25/2022

  Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.

• Lakewood-Amedex Appoints Chief Medical Officer and Adds New Management Team Members

  1/19/2022

  Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.

• Lakewood-Amedex Receives Notice of Allowance for Two U.S. Patents Covering the Broad-Spectrum Antimicrobial Nu-8 Bisphosphocin®

  5/27/2020

  Lakewood-Amedex Inc. announced that the U.S. Patent and Trademark Office has issued a "Notice of Allowance" for two broad patent applications related to the Company's broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled "Antimicrobial Compounds, Compositions, and Uses Thereof." The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.

• Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas

  1/17/2019

  Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection and promote wound healing in patients with chronic diabetic foot ulcers (cDFU).

• Lakewood-Amedex Inc. Elects Stephen Evans-Freke as New Chairman of the Board of Directors

  5/11/2018

  Mr. Evans-Freke is Co-Founder and Managing General Partner of Auven Therapeutics

• Lakewood-Amedex Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection

  12/4/2017

  Lakewood-Amedex today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies.

• Lakewood-Amedex Inc. Reports Positive Top-Line Data From Randomized Controlled Phase I/IIa Trial Of Nu-3 Antimicrobial In Patients With Infected Diabetic Foot Ulcers

  9/27/2017

• Lakewood-Amedex Inc. Completes Clinical Trial Recruitment For Final Cohort Of The Company's Phase I/IIa Program In Patients With Infected Diabetic Foot Ulcers

  8/23/2017

• Lakewood-Amedex Inc. Advances Novel Bisphosphocin Nu-8 Compound Based On Encouraging Pre-Clinical Results

  4/4/2017

• Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs

  5/26/2016

• Lakewood-Amedex Inc. Announces Its Novel Bisphospocin Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes

  5/19/2015

• Lakewood-Amedex Inc. Announces Expanded Research Collaboration With The University Of Jyvaskyla Following Promising Results Demonstrating Bisphosphocin Activity Against Borrelia Burgdorferi

  3/12/2015

• Lakewood-Amedex Inc. Submits Investigational New Drug Application For Bisphosphocin Nu-3 For The Treatment Of Diabetic Foot Infections

  12/11/2014

• Lakewood-Amedex Inc. Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology

  9/11/2014

• Lakewood-Amedex Inc. Raises $5.5 Million In Series C Preferred Stock Financing

  6/18/2014

• Lakewood-Amedex Inc. Signs Strategic Advisory Agreement With H.C. Wainwright & Co.

  10/9/2013

• Lakewood-Amedex Inc. to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference

  9/11/2013

• Lakewood-Amedex Inc. Announces Its Novel Bisphosphocin Class of Antimicrobials are Active Against NDM-1 Positive Bacterial Strains

  8/1/2013

• Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome

  1/27/2011